Dr. Ebrahim Haroon




Academic Degree(s)






Current Position

  • Assistant Professor of Psychiatry and Behavioral Sciences, Emory University School of Medicine


Professional Experience

  • Assistant Professor of Psychiatry, Madras University Medical College, Chennai, India, 1988-1994
  • Assistant Professor of Psychiatry and Biobehavioural Sciences, University of California, Los Angeles, 2003-2006
  • Assistant Professor of Psychiatry and Behavioural Sciences, Atlanta, GA


Education & Training

  • Bachelor of Medicine & Surgery (MBBS), Madurai University Medical College, India, 1975-1981.
  • Doctorate in Medicine (Psychiatry), Madras University Medical College, India, 1982-1984
  • Residency in Psychiatry, Yale University 1994-1998



  • Seymour L Lustman Award, Yale University, 1997
  • Paul E Kaunitz Award, Yale University, 1998
  • Young Investigator Award, National Association for Research on Schizophrenia and Affective Disorders, 2010
  • Career Development Award, National Institute of Mental Health,
  • New Investigator Award, American Society for Clinical Psychopharmacology – NCDEU, 2013


Research Grants

  • R01MH107033, Inflammation-Induced CNS Glutamate as a Function of Depression in Middle Age. National Institute of Mental Health 
  • R01MH112076, Inflammation-Induced CNS Changes as A Function Of Depression, National Institute of Mental Health


Committee & Membership

  • Scientific Program Committee, American Society for Clinical Psychopharmacology.
  • Scientific Program Committee, Society for Biological Psychiatry
  • Editorial Board, Brain, Behavior and Immunity.


Selected Publication

  • Haroon E, Watari K, Thomas A, Ajilore O, Mintz J, Elderkin-Thompson V, et al. (2009): Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients. Psychiatry Res. 171:10-19.
  • Haroon E, Raison CL, Miller AH (2012): Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 37:137-162.
  • Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR, et al. (2014): IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology. 39:1777-1785.
  • Haroon E, Felger JC, Woolwine BJ, Chen X, Parekh S, Spivey JR, et al. (2015): Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings. Brain Behav Immun. 46:17-22.
  • Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T, et al. (2016): Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry. 21:1351-1357.
  • Haroon E, Mayberg H (2017): Brain Imaging in Psychopharmacology. In: Schatzberg AF, Nemeroff CB, editors. American Psychiatric Publishing Textbook of Psychopharmacology, Fifth Edition ed. Arlington, VA: The American Psychiatric Press pp 239-277.
  • Haroon E, Miller AH (2017): Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications. Curr Top Behav Neurosci. 31:173-198.
  • Haroon E, Miller AH (2017): Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders. Mod Trends Pharmacopsychiatry. 31:37-55.
  • Haroon E, Miller AH, Sanacora G (2017): Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology. 42:193-215.
  • Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, et al. (2018): Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology. 95:43-49